CZ2016538A3 - Farmaceutická kompozice obsahující dvě rozdílné účinné látky - Google Patents

Farmaceutická kompozice obsahující dvě rozdílné účinné látky Download PDF

Info

Publication number
CZ2016538A3
CZ2016538A3 CZ2016-538A CZ2016538A CZ2016538A3 CZ 2016538 A3 CZ2016538 A3 CZ 2016538A3 CZ 2016538 A CZ2016538 A CZ 2016538A CZ 2016538 A3 CZ2016538 A3 CZ 2016538A3
Authority
CZ
Czechia
Prior art keywords
ezetimibe
rosuvastatin
pharmaceutically acceptable
acceptable salt
tablets
Prior art date
Application number
CZ2016-538A
Other languages
Czech (cs)
English (en)
Inventor
Alena Prokopová
Jaroslava Svobodová
Ondřej Dammer
Petr Mikeš
Original Assignee
Zentiva, K.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva, K.S. filed Critical Zentiva, K.S.
Priority to CZ2016-538A priority Critical patent/CZ2016538A3/cs
Priority to PCT/CZ2017/050036 priority patent/WO2018041281A1/en
Priority to TW106129833A priority patent/TW201821063A/zh
Publication of CZ2016538A3 publication Critical patent/CZ2016538A3/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CZ2016-538A 2016-09-05 2016-09-05 Farmaceutická kompozice obsahující dvě rozdílné účinné látky CZ2016538A3 (cs)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CZ2016-538A CZ2016538A3 (cs) 2016-09-05 2016-09-05 Farmaceutická kompozice obsahující dvě rozdílné účinné látky
PCT/CZ2017/050036 WO2018041281A1 (en) 2016-09-05 2017-08-31 A pharmaceutical composition comprising rosuvastatin and ezetimibe and a preparation method thereof
TW106129833A TW201821063A (zh) 2016-09-05 2017-08-31 包含兩種不同活性成分的醫藥組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CZ2016-538A CZ2016538A3 (cs) 2016-09-05 2016-09-05 Farmaceutická kompozice obsahující dvě rozdílné účinné látky

Publications (1)

Publication Number Publication Date
CZ2016538A3 true CZ2016538A3 (cs) 2018-03-14

Family

ID=59955310

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ2016-538A CZ2016538A3 (cs) 2016-09-05 2016-09-05 Farmaceutická kompozice obsahující dvě rozdílné účinné látky

Country Status (3)

Country Link
CZ (1) CZ2016538A3 (zh)
TW (1) TW201821063A (zh)
WO (1) WO2018041281A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021019499A1 (en) 2019-07-31 2021-02-04 TECNIMEDE - Sociedade Técnico-medicinal, SA Solid oral multiple-unit immediate release compositions, methods and uses thereof
KR102496243B1 (ko) * 2020-01-14 2023-02-07 일동제약(주) 아토르바스타틴 및 에제티미브를 포함하는 정제
CN114280181B (zh) * 2021-12-23 2024-06-18 浙江海翔川南药业有限公司 一种瑞舒伐他汀中间体及其有关物质的检测方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009024889A2 (en) 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
WO2011019326A2 (en) 2009-07-02 2011-02-17 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation
BR112012002069B8 (pt) * 2009-07-28 2021-05-25 Egis Gyogyszergyar Nyilvanosan Muekodo Reszvenytarsasag processo para a fabricação de um granulado contendo ezetimibe microcristalino
TR201009397A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Rosuvastatin içeren farmasötik bileşimler.
WO2013066279A1 (en) 2011-10-13 2013-05-10 Mahmut Bilgic Solid dosage forms comprising ezetimibe
DK2844233T3 (da) 2012-05-01 2020-07-13 Althera Life Sciences Llc Oral tabletformulering bestående af en fastsat kombination af rosuvastatin og ezetimib til behandling af hyperlipidæmi og kardiovaskulære sygdomme
MX2012014970A (es) * 2012-12-18 2013-08-27 Hetlabs Mexico S A De C V Composiciones farmaceuticas que comprenden ezetimiba y rosuvastatina de calcio amorfo novedoso.
HU231036B1 (hu) 2013-09-30 2019-12-30 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Koleszterin bioszintézis gátló hatóanyagot és koleszterin abszorpciót gátló hatóanyagot tartalmazó kombinációs gyógyszerkészítmény
CN103585157B (zh) * 2013-11-13 2016-02-03 武汉武药科技有限公司 一种含依折麦布和瑞舒伐他汀的双层片及其制备方法
KR20150079373A (ko) 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
KR101977785B1 (ko) 2014-06-25 2019-05-14 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 및 그 제조방법

Also Published As

Publication number Publication date
TW201821063A (zh) 2018-06-16
WO2018041281A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
US20200163882A1 (en) Solid Pharmaceutical Compositions Of Androgen Receptor Antagonists
EP2830618B1 (en) Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt
US11883403B2 (en) Pharmaceutical compositions comprising Afatinib
EP2542224B1 (en) Dabigatran etexilate-containing oral pharmaceutical composition
EP2068835A2 (en) Imatinib compositions
US11786526B2 (en) Pharmaceutical composition comprising rosuvastatin and ezetimibe and a preparation method thereof
US10603282B2 (en) Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
CZ2016538A3 (cs) Farmaceutická kompozice obsahující dvě rozdílné účinné látky
US11576917B2 (en) Pharmaceutical compositions comprising Ibrutinib
WO2011080706A1 (en) Enhanced solubility of ziprasidone
US11260055B2 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
WO2015069203A1 (en) Capsule comprising rupatadine fumarate and montelukast sodium
ES2898456T3 (es) Composición farmacéutica que comprende un agente antifúngico triazol y método de preparación de la misma
TW201801725A (zh) 含非晶索非那新的口服固體製劑及其製備方法
EA040745B1 (ru) Фармацевтическая композиция, содержащая два различных активных ингредиента, и способ ее получения
WO2024115680A1 (en) Ribociclib salts and formulations thereof
WO2023195022A1 (en) Stable pharmaceutical compositions comprising erdafitinib
US20130273158A1 (en) Extended release compositions of quetiapine
JP2020075923A (ja) エルロチニブを有効成分とする医薬錠剤
JP2020147511A (ja) レボセチリジン塩酸塩を含む医薬組成物及び医薬製剤、並びにレボセチリジン塩酸塩の安定化方法